Search
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigationalSarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Foreskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedSkin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers. … The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes.
Nelarabine
go.drugbank.com/drugs/DB01280ApprovedInvestigational[A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879] … Nelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalThough it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalA propylamine formed from the cyclization of the side chain of amphetamine. … Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalCompared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational(HoFH) under the brand name "Evkeeza". … [A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with